Regen Therapeutics, also known as ReGen (Therapeutics Plc), was founded in February 1998 with the mission to develop Colostrinin™. Colostrinin™ is a proline-rich polypeptide complex derived from mammalian colostrum and is believed to have potential therapeutic applications in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis. With a commitment to advancing medical research, Regen Therapeutics provides a range of products and conducts extensive research in the field.

Their portfolio includes Colostrinin™ as a nutraceutical and pharmaceutical peptides, as well as Zolpidem. These products aim to address various health conditions and improve overall well-being. Regen Therapeutics actively shares their findings through presentations, news announcements, and events.

They offer email news alerts to keep their customers informed. The brand values accessibility, emphasizing their dedication to providing accurate and reliable information. For further information or to stay updated with Regen Therapeutics, visitors can navigate their user-friendly website, which includes a comprehensive sitemap and contact details